Pharmaceutical

United States Scleroderma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:36pm

The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Scleroderma Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Scleroderma pipeline products, Scleroderma epidemiology, Scleroderma market valuations and forecast, Scleroderma drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Scleroderma treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Scleroderma products

Europe Migraine Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:20pm

The "Europe Migraine Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Migraine Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Migraine Market and Competitive Landscape - 2020, provides comprehensive insights into the Migraine pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Migraine market size and drug sales.
  • This research covers the following:
    Migraine treatment options, Migraine late stage clinical trials pipeline, Migraine prevalence by countries, Migraine market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.

Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer

Friday, September 18, 2020 - 4:11pm

Nemaura Medical, Inc. (NASDAQ: NMRD)(Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin Mclarney as Chief Finance Officer, effective September 15, 2020.

Key Points: 
  • Nemaura Medical, Inc. (NASDAQ: NMRD)(Nemaura or the Company), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin Mclarney as Chief Finance Officer, effective September 15, 2020.
  • Dr. Faz Chowdhury, Nemaura Medicals Chief Executive Officer commented, We are very pleased to welcome Justin to Nemaura.
  • Mr. Mclarney brings with him a wealth of experience within International Finance, Accounting, and Process Development & Control and has been a Chartered Accountant since 1999.
  • Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

United Methicillin Resistant Staphylococcus Aureus (MRSA) Infections Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 3:50pm

The "US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Methicillin Resistant Staphylococcus Aureus Infections Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Methicillin Resistant Staphylococcus Aureus Infections pipeline products, Methicillin Resistant Staphylococcus Aureus Infections epidemiology, Methicillin Resistant Staphylococcus Aureus Infections market valuations and forecast, Methicillin Resistant Staphylococcus Aureus Infections drugs sales and competitive landscape in the US.
  • Methicillin Resistant Staphylococcus Aureus Infections pipeline: Find out the products in clinical trials for the treatment of Methicillin Resistant Staphylococcus Aureus Infections by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Methicillin Resistant Staphylococcus Aureus Infections epidemiology: Find out the number of patients diagnosed (prevalence) with Methicillin Resistant Staphylococcus Aureus Infections in the US
    Methicillin Resistant Staphylococcus Aureus Infections drugs: Identify key products marketed and prescribed for Methicillin Resistant Staphylococcus Aureus Infections in the US, including trade name, molecule name, and company
    Methicillin Resistant Staphylococcus Aureus Infections drugs sales: Find out the sales revenues of Methicillin Resistant Staphylococcus Aureus Infections drugs in the US
    Methicillin Resistant Staphylococcus Aureus Infections market valuations: Find out the market size for Methicillin Resistant Staphylococcus Aureus Infections drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Methicillin Resistant Staphylococcus Aureus Infections drugs market share: Find out the market shares for key Methicillin Resistant Staphylococcus Aureus Infections drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Methicillin Resistant Staphylococcus Aureus Infections products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005395/en/

United States Osteoporosis Market and Competitive Landscape Report 2020: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2016-2025 - ResearchAndMarkets.com

Friday, September 18, 2020 - 3:30pm

The "US Osteoporosis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Osteoporosis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Osteoporosis Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Osteoporosis pipeline products, Osteoporosis epidemiology, Osteoporosis market valuations and forecast, Osteoporosis drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Osteoporosis treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Osteoporosis products

Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

Friday, September 18, 2020 - 4:00pm

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the companys Board of Directors.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the companys Board of Directors.
  • I am thrilled that Lori will be joining the Pipeline board as an independent director, said Carmine Stengone, President & CEO of Pipeline Therapeutics.
  • Im excited to be joining Pipelines Board of Directors not long after the companys lead development candidate, PIPE-505, entered the clinic, said Ms. Lyons-Williams.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.

Global Big Pharma Partnering Deal Terms and Agreements Directory 2020: Access Agreements Announced in the Life Sciences Since 2014 - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:53pm

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.

Key Points: 
  • Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals.
  • This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.
  • The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
    Available deals are listed by:

Global Preclinical Stage Partnering Deal Terms and Agreements in Pharma and Biotech Directory 2014-2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:48pm

The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.
  • The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals.
  • This report contains a comprehensive listing of over 1,800 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties.
  • Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 includes:
    Available contracts are listed by:

Global Pharma and Biotech Clinical Stage Partnering Deal Terms and Agreements Report 2014-2020: Comprehensive Listing of Over 2,300 Clinical Stage Partnering Deals - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:39pm

The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.
  • This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties.
  • Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020 includes:
    Available contracts are listed by:

Global Pharmaceutical Partnering Deal Terms and Agreements Analysis Report 2016-2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 2:34pm

The "Global Pharmaceutical Partnering Terms and Agreements 2016-2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pharmaceutical Partnering Terms and Agreements 2016-2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Pharmaceutical Partnering Terms and Agreements 2016 to 2020 report provides a detailed understanding and analysis of how and why companies enter Pharmaceutical partnering deals.
  • The report takes the reader through a comprehensive review Pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Pharmaceutical partnering deals.
  • Insight into terms included in a Pharmaceutical partnering agreement, with real world examples
    Available deals are listed by: